Haemonetics Reports 5.3% Revenue Decline in Q2 Fiscal 2026, Operating Income Increases 13.1%

Haemonetics Corporation reported a decline in net revenues for the second quarter of fiscal 2026, with revenues totaling $327.3 million, down 5.3% from $345.5 million in the same period last year. For the six months ended September 27, 2025, revenues decreased by 4.8% to $648.7 million compared to $681.7 million in the prior year. The decrease was primarily attributed to revenue declines in the Plasma and Blood Center segments, driven by a customer transition at CSL Plasma and the divestiture of the Whole Blood product line. However, the Hospital segment saw a revenue increase, largely due to growth in the Hemostasis Management product line.

Despite the revenue decline, Haemonetics experienced an increase in operating income, which rose 13.1% to $58.5 million for the three months ended September 27, 2025, and 22.9% to $112.4 million for the six-month period. This improvement was attributed to pricing benefits across all business units, a favorable product mix, and reduced restructuring costs. The company reported a net income of $38.7 million for the quarter, a 14.3% increase from $33.8 million in the prior year, resulting in a diluted earnings per share of $0.81, up from $0.66.

Operationally, Haemonetics has been active in strategic initiatives, including the completion of an accelerated share repurchase program, which repurchased $75 million of its common stock. The company also made significant investments in acquisitions, including Attune Medical and OpSens, which are expected to enhance its product offerings in the Hospital segment. The company’s total employee headcount as of September 27, 2025, was not disclosed, but the filing indicated ongoing restructuring efforts aimed at improving operational efficiency.

Geographically, the company generated 26.6% of its sales outside the U.S. during the quarter, with international revenues totaling $87.2 million. The company has implemented foreign currency hedges to mitigate risks associated with currency fluctuations, particularly in the Japanese Yen and Euro. Looking ahead, Haemonetics anticipates continued challenges in the Plasma and Blood Center segments but remains optimistic about growth opportunities in the Hospital segment, supported by its recent acquisitions and product innovations. The company expects to maintain its focus on operational excellence and strategic investments to drive long-term growth.